Clinical trial
S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney…
NCT00311545 · SWOG Cancer Research Network, Other · Withdrawn
Key facts
| NCT number | NCT00311545 |
|---|---|
| Title | S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer |
| Official title | A Phase II Study of CNTO 328, A Monoclonal Antibody Against Interleukin-6 (IL-6), In Patients With Advanced or Metastatic Renal Cell Cancer |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Biological |
| Interventions | CNTO 328 |
| Enrollment | 0 |
| First posted | Apr 6, 2006 |
| Last update posted | Feb 20, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: